Finch Therapeutics Group, Inc.
DelistedCIK 1733257fmd_1Y30SVWT6F1CGV1F0H2V85HYYNManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Jun 30, 2024, 18 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|
| Total revenues | 8 | 19 | 1 | 0 |
| Research and development | 33 | 57 | 53 | 7 |
| Total operating expenses | 47 | 79 | 116 | 84 |
| Operating income | (39) | (60) | (116) | (84) |
| Other non-operating income (expense) | 0 | 2 | 1 | 6 |
| Income before taxes | (39) | (58) | (115) | (78) |
| Income tax expense | 0 | 0 | 0 | (3) |
| Net income from continuing operations | (39) | (58) | (115) | (75) |
| Net income | (39) | (58) | (115) | (75) |
| Net income to common shareholders | (39) | (58) | (115) | (75) |